The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients

Oncotype DX testing is reimbursed in Israel for node-negative and node-positive (N1+; up to 3 positive nodes including micrometastases), estrogen receptor positive (ER+), breast cancer patients. This retrospective study evaluated the impact of Oncotype DX testing on treatment decisions in N1+/ER+ br...

Descripción completa

Detalles Bibliográficos
Autores principales: Stemmer, Salomon M., Klang, Shmuel H., Ben-Baruch, Noa, Geffen, David B., Steiner, Mariana, Soussan-Gutman, Lior, Merling, Shahar, Svedman, Christer, Rizel, Shulamith, Lieberman, Nicky
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2013
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3706725/
https://www.ncbi.nlm.nih.gov/pubmed/23801158
http://dx.doi.org/10.1007/s10549-013-2603-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3706725/
https://www.ncbi.nlm.nih.gov/pubmed/23801158
http://dx.doi.org/10.1007/s10549-013-2603-1

Ejemplares similares